Xuejing Chen
Ophthalmology · Taunton, MANPI 1033484159
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Alcon at 36.1% of the total. Reporting peaked in 2019 at $2,165 and has fallen 89.8% since, to $222 in 2025.
Across 25 payments — averaging $190.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Beaver-visitec International, Inc.$2K
- Novartis$345
- Genentech USA, Inc.$252
- Apellis Pharmaceuticals, Inc.$135
- Alimera Sciences, Inc.$122
- plus $591 from 7 others
What the payments were for
- Consulting fees$1,60034%
- Travel & lodging$89519%
- Food & beverage$2,23447%
- Education$170%
- Entertainment$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 7 | $1,718 |
| Beaver-visitec International, Inc. | 2 | $1,600 |
| Novartis | 4 | $345 |
| Genentech USA, Inc. | 2 | $252 |
| Apellis Pharmaceuticals, Inc. | 2 | $135 |
| Alimera Sciences, Inc. | 1 | $122 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| AbbVie | 1 | $107 |
| Regeneron | 1 | $107 |
| Medtronic | 1 | $97 |
| Regeneron Healthcare Solutions, Inc. | 1 | $79 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Optos, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,763 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 24 | $2,672 |
| Bromfenac Sodium | 11 | $1,420 |
| Prednisolone Acetate | 16 | $775 |
| Diclofenac Sodium | 24 | $263 |
| Latanoprost | 22 | $206 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $185 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Taunton
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.